semaglutide off the market Biosimilar and Generic Size, Share and Latest Trends 2026 to 2035 Deadline to stop selling cheaper

Both firms continue to invest heavily - Novo Nordisk in Kalundborg and North Carolina, Lilly across Indiana, North Carolina, and Wisconsin - expanding peptide synthesis and fill-finish capacity that fortify supply leadership

Theyre only sold from US suppliers for research purposes

When you eat, semaglutide stimulates insulin production, which may cause low blood sugar (glucose) levels, especially in people with diabetes

Their mechanism of action, which includes glucose control, weight loss promotion, and cardiovascular benefits, makes them a favorable choice for patients seeking effective and safe antidiabetic therapy